Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion

Core Insights - Gilead Sciences has agreed to acquire the remaining stake in development partner Arcellx, valuing the biotechnology company at approximately $7.8 billion upon closing [1] Company Summary - The acquisition signifies Gilead Sciences' commitment to expanding its portfolio in the biotechnology sector [1] - Arcellx is positioned to enhance Gilead's capabilities in developing innovative therapies [1]